Change: + 1.38
Day High: 4.75
Day Low: 4.05
2:19 PM ET | Feb 24, 2017
Delayed 20 min., by eSignal.
David Zaccardelli Pharm.D.
Acting Chief Executive Officer
From 2004 until 2016, Dr. Zaccardelli served in several senior management roles at United Therapeutics, including chief operating officer, chief manufacturing officer and executive vice president, pharmaceutical development and operations. Prior to joining United Therapeutics, Dr. Zaccardelli founded and led a startup company focused on contract pharmaceutical development services, from 1997 through 2003. From 1988 to 1996, Dr. Zaccardelli worked at Burroughs Wellcome & Co. and Glaxo Wellcome, Inc. in a variety of clinical research positions. He also served as director of clinical and scientific affairs for Bausch & Lomb Pharmaceuticals from 1996 to 1997. Dr. Zaccardelli received his Doctor of Pharmacy degree from the University of Michigan.
President and Chief Commercial Officer
Mr. Moore is responsible for commercial development. He has spent over 15 years developing and managing pharmaceutical commercial programs, with the majority of those years spent with the Ortho-McNeil and Janssen Pharmaceutical divisions within Johnson & Johnson. Mr. Moore has held leadership roles in key sales and marketing functions, and was part of teams that developed and executed launch plans for several prescription pharmaceuticals for both primary and acute care settings. He developed payer value platforms for several therapeutic areas including antibiotics, pain and women’s health, in which he successfully implemented pricing and reimbursement strategies with hospitals and managed care organizations. Following Johnson & Johnson, he was chief business officer and vice president of Worldwide Commercial Operations of Tranzyme, Inc., where he was responsible for building the commercial organization as well as in- and out-licensing clinical-stage assets and was chief business officer of Ocera Therapeutics where he was responsible for developing the commercial plans for an Orphan-designated advanced liver disease product for both the community and acute care markets. Mr. Moore received his B.Sc. in Biology from Towson University and an M.B.A. from Lehigh University, and a second graduate degree in Health Policy Excellence from Thomas Jefferson University.
Mark W. Hahn
Executive Vice President and Chief Financial Officer
David Oldach M.D., FIDSA
Chief Medical Officer
David Oldach joined Cempra Pharmaceuticals in 2011. Between 2006 and 2011, Dr. Oldach directed clinical research at Gilead Sciences, Inc., where his drug development experience ranged from IND/first-in-human trial development and execution through NDA-supportive Phase 3 protocol development and execution. Dr. Oldach received his Medical Degree, Magna Cum Laude, from the University of Maryland School of Medicine and completed a residency in Internal Medicine at the Massachusetts General Hospital. He completed an Infectious Disease Fellowship at Johns Hopkins University School of Medicine, serving under John Bartlett. His academic clinical research included studies in community-acquired pneumonia and surgical infections, as well as HCV pathogenesis. At the time of his transition from academic medicine to industry, Dr. Oldach was a tenured Associate Professor of Medicine at the University of Maryland School of Medicine and served as the Infectious Diseases Section Chief in the Baltimore Veterans Administration Hospital.
Executive Vice President, Investor Relations and Corporate Communications
Prior to joining Cempra, Mr. Bluth headed investor relations and corporate communications for two of Silicon Valley’s leading biotechnology companies, CV Therapeutics, which was acquired in 2009, and Aviron, which was acquired in 2002. Before joining Aviron, Mr. Bluth led the west coast healthcare practice for Fleishman-Hillard, an international public relations firm. From 2009-2012, he was senior vice president of investor relations and group communications at German-based Elster Group, one of the world’s largest electricity, gas and water measurement and control providers. Mr. Bluth served as a member of Elster’s group executive board and built the investor relations and corporate communications functions for the company through its initial public offering in 2009. Elster was acquired in 2012. From 2012 through mid-2016, Mr. Bluth was senior vice president of investor relations and corporate communications and served on the executive committee at PowerSecure International, Inc., a leading provider of energy technologies and services to electric utilities and their large industrial, commercial, institutional and municipal customers. PowerSecure was acquired in May 2016. Mr. Bluth holds a Bachelor’s degree in physiology from Cornell University.
Carl T. Foster
Executive Vice President, Business Development
Gary Horwith M.D.
Executive Vice President, Quality and Safety
Dr. Horwith oversees regulatory chemistry, manufacturing and controls (CMC) and clinical strategies. He has 30 years of experience in clinical research and regulatory affairs and has brought numerous NCEs, vaccines, and other biological products to the IND stage, conducted Phase 1-to-3 trials and filed several NDAs during his 11 years at Wyeth and 19 years at other biotechnology and biopharmaceutical companies. Dr. Horwith received his M.D. from Autonomous University of Guadalajara, completed a residency in Internal Medicine at the University of Connecticut, an Infectious Disease Fellowship at University of California Irvine, and was a principal investigator at the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) before entering the pharmaceutical industry.